<code id='4A951D08E5'></code><style id='4A951D08E5'></style>
    • <acronym id='4A951D08E5'></acronym>
      <center id='4A951D08E5'><center id='4A951D08E5'><tfoot id='4A951D08E5'></tfoot></center><abbr id='4A951D08E5'><dir id='4A951D08E5'><tfoot id='4A951D08E5'></tfoot><noframes id='4A951D08E5'>

    • <optgroup id='4A951D08E5'><strike id='4A951D08E5'><sup id='4A951D08E5'></sup></strike><code id='4A951D08E5'></code></optgroup>
        1. <b id='4A951D08E5'><label id='4A951D08E5'><select id='4A951D08E5'><dt id='4A951D08E5'><span id='4A951D08E5'></span></dt></select></label></b><u id='4A951D08E5'></u>
          <i id='4A951D08E5'><strike id='4A951D08E5'><tt id='4A951D08E5'><pre id='4A951D08E5'></pre></tt></strike></i>

          hotspot

          hotspot

          author:hotspot    Page View:66842
          US Capitol - SOTU
          Lawmakers in Congress have decided to punt efforts to reform how PBMs operate. BRENDAN SMIALOWSKI/AFP/Getty Images

          WASHINGTON — Congress has abandoned its attempt to reform how pharmacy middlemen operate in an upcoming package to fund the federal government, 11 lobbyists and sources following the talks told STAT.

          It’s a missed opportunity to pass one of the health care priorities that has attracted the most bipartisan interest and activity this Congress, though lawmakers could revive the negotiations on the issues in the future.

          advertisement

          Reforming how pharmacy benefit managers operate has been a top lobbying priority for the pharmaceutical industry since Democrats passed a major package aimed at lowering the costs of medicines in 2022. Pharma and PBMs have taken up a very public battle on the airwaves.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          ChatGPT in medicine: STAT answers readers' burning questions
          ChatGPT in medicine: STAT answers readers' burning questions

          MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

          read more
          The woman behind the Dana Farber
          The woman behind the Dana Farber

          LaurieGlimcher,CEOofDanaFarberCancerInstitute,isthearchitectofthebiggestshakeupinBostonhealthcareind

          read more
          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more

          Supreme Court wrestles with OxyContin maker's bankruptcy deal

          STEFANIREYNOLDS/AFPviaGettyImagesWASHINGTON—TheSupremeCourtonMondaywrestledwithanationwidesettlement